AR063499A1 - Compuestos derivados de la pirrolidona y un proceso para su preparacion - Google Patents
Compuestos derivados de la pirrolidona y un proceso para su preparacionInfo
- Publication number
- AR063499A1 AR063499A1 ARP070104658A ARP070104658A AR063499A1 AR 063499 A1 AR063499 A1 AR 063499A1 AR P070104658 A ARP070104658 A AR P070104658A AR P070104658 A ARP070104658 A AR P070104658A AR 063499 A1 AR063499 A1 AR 063499A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- independently selected
- optionally
- het
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Los compuestos de la invencion pueden ser utiles en el tratamiento o la prevencion de una enfermedad o afeccion médica mediada a través de la glucoquinasa (GLK) tal como la diabetes tipo 2. La invencion se refiere asimismo a un método para la preparacion de compuestos de formula 1 Reivindicacion 1: Un compuesto de formula (1): donde se selecciona de alquilo (C1-4) y cicloalquilo (C3-6); HET-1 es un anillo heteroarilo unido a través de C, de 5 o 6 miembros, que contiene un átomo de nitrogeno en la posicion 2 respecto del nitrogeno amídico al que está unido el anillo y de manera opcional otros 1 o 2 heteroátomos anulares, seleccionados independientemente de O, N y S; anillo que está sustituido de manera opcional en cualquier átomo de nitrogeno (con la condicion de que no se produzca así cuaternizacion) con un sustituyente seleccionado de R7 y/o en 1 o 2 átomos de carbono disponibles con un sustituyente seleccionado independientemente de R6; el anillo A se selecciona de fenilo, HET-2 y HET-3; donde cuando el anillo A es fenilo, está sustituido con R2 y de manera opcional sustituido además con un grupo seleccionado de R3; R2 se selecciona de -C(O)NR4R5, SOpR4 y -SO2NR4R5; R3 se selecciona de halo, metilo y trifluormetilo; R4 se selecciona de hidrogeno, alquilo (C1-4) [de manera opcional sustituido con 1 o 2 sustituyentes seleccionados independientemente de HET-5, -OR5, -SO2R5, cicloalquilo (C3-6) (sustituido de manera opcional con 1 grupo seleccionado de R15) y -C(O)NR5R5], cicloalquilo (C3-6) (sustituido de manera opcional con 1 grupo seleccionado de R15) y HET-5; HET-5 es un anillo heterociclilo unido a través de C o N, de 4, 5 o 6 miembros, que contiene 1, 2, 3 o 4 heteroátomos seleccionados independientemente de O, N y S, donde un grupo -CH2 puede de manera opcional reemplazarse por un -C(O)-, y donde un átomo de azufre del anillo heterocíclico puede de manera opcional estar oxidado a un grupo S(O) o S(O)2 anillo que está sustituido de manera opcional en un átomo de carbono o nitrogeno disponible con 1 o 2 sustituyentes alquilo (C1-4); R5 es hidrogeno o alquilo (1-4C); o R4 y R5 junto con el átomo de nitrogeno al que están unidos forman un anillo heterociclilo saturado o parcialmente insaturado de 4 a 7 miembros, que contiene de manera opcional 1 o 2 heteroátomos adicionales (además del átomo de N conector) seleccionados independientemente de O, N y S, donde un grupo -CH2- puede de manera opcional reemplazarse por un -C(O)- y donde un átomo de azufre del anillo puede de manera opcional estar oxidado a un grupo S(O) o S(O)2 anillo que está sustituido de manera opcional en un átomo de carbono disponible con 1 o 2 sustituyentes seleccionados independientemente de R8 y/o en un átomo de nitrogeno disponible con un sustituyente seleccionado de R9; o R4 y R5 junto con el átomo de nitrogeno al que están unidos forman un anillo heterociclilo saturado o parcialmente insaturado bicíclico de 6-10 miembros, que contiene de manera opcional 1 átomo de nitrogeno adicional (además del átomo de N conector), donde un grupo -CH2- puede de manera opcional reemplazarse con un -C(O)-; anillo que está sustituido de manera opcional en un carbono disponib!e con 1 sustituyente seleccionado de hidroxi, metilo y halo, o en un átomo de nitrogeno disponible con metilo; R6 se selecciona independientemente de alquilo (C1-4), halo, hidroxialquilo (C1-4), alcoxi (C1-4)-alquilo (C1-4), alquil (C1-4)-S(O)p-alquilo (C1- 4), aminoalquilo (C1-4), alquil-(C1-4)-aminoalquilo (C1-4) y dialquil-(C1-4)- aminoalquilo (C1-4); R7 se selecciona independientemente de alquilo (C1-4), hidroxialquilo (C1-4), alcoxi (C1-4)-alquilo (C1-4), alquilo (C1-4)-S(O)p-alquilo (C1-4), aminoalquilo (C1-4), alquil-(C1-4)-aminoalquilo (C1-4) y dialquil-(C1-4)-aminoalquilo (C1-4); R8 se selecciona de hidroxi, alcoxi (C1-4), alquilo (C1-4), aminocarbonilo, alquilaminocarbonilo (C1-4), dialquilaminocarbonilo (C1-4), alquilamino (C1-4), dialquilamino (C1-4), alcoxi (C1-4)-alquilo (C1-4), hidroxialquilo (C1-4) y -S(O)p- alquilo (C1-4); R9 se selecciona de alquilo (C1-4), -C(O)alquilo (C1-4), aminocarbonilo, alquilaminocarbonilo (C1-4), dialquilaminocarbonilo (C1-4), alcoxi (C1-4)- alquilo (C1-4), hidroxialquilo (C1 -4) y -S(O)p-alquilo (C1-4); HET-2 es un anillo heteroarilo de 5 o 6 miembros, que contiene 1, 2 o 3 heteroátomos anulares seleccionados independientemente de O, S y N; anillo que está sustituido en un átomo de carbono disponible con un sustituyente seleccionado de R2, y de manera opcional está además sustituido en 1 o 2 átomos de carbono disponibles con un sustituyente seleccionado independientemente de R3 y/o en un átomo de nitrogeno disponible (con la condicion de que no se produzca así cuaternizacion) con un sustituyente seleccionado de R10 se selecciona de alquilo (C1-4), cicloalquilo (C3-6), hidroxialquilo (C1- 4), alcoxi (C1-4)-alquilo (C1-4), -C(O)alquilo (C1-4), bencilo y alquilsulfonilo (C1-4); HET-3 es un sistema anular bicíclico fusionado de formula -B-C; donde B es un anillo directamente unido al átomo de oxigeno conector y el anillo B es fenilo o es un anillo heteroarilo de 5 o 6 miembros que contiene 1, 2 o 3 heteroátomos seleccionados independientemente de O, N y S (con la condicion de que no haya uniones O-O, S-S u O-S en el anillo); donde el anillo B está sustituido de manera opcional en cualquier átomo de nitrogeno con un sustituyente seleccionado de R11 y/o en cualquier átomo de carbono disponible con 1 o 2 sustituyentes seleccionados independientemente de R12; R11 se selecciona independientemente de alquilo (C1-4), hidroxialquilo (C1-4), alcoxi (C1-4)-alquilo (C1-4), alquil (C1-4)-S(O)p-alquilo (C1-4), aminoalquilo (C1 -4), alquil-(C1-4)-aminoalquilo (C1-4), dialquil-(C1-4)-aminoalquilo (C1-4) y HET-4; R12 se selecciona independientemente de alquilo (C1-4), halo, hidroxialquilo (C1-4), alcoxi (C1-4)-alquilo (C1-4), alquil (C1-4)-S(O)p-alquilo (C1- 4), aminoalquilo (C1-4), alquil (C1-4)-aminoalquilo (C1-4), dialquil (C1-4)- aminoalquilo (C1-4) y HET-4; HET-4 es un anillo heteroarilo no sustituido unido a través de C o N, de 5 o 6 miembros, que contiene 1, 2 o 3 heteroátomos anulares seleccionados independientemente de O, N y S; el anillo C es un anillo heterociclico de 5-7 miembros fusionado con el anillo B, que contiene 1, 2 o 3 heteroátomos anulares seleccionados independientemente de O, S y N (con la condicion de que no haya uniones O-O, S-O o S-S en el anillo), donde cualquier átomo de carbono o azufre del anillo puede de manera opcional estar oxidado y donde el anillo C está sustituido de manera opcional en cualquier átomo de nitrogeno con un sustituyente seleccionado de R13 y/o en cualquier átomo de carbono disponible con 1 o 2 sustituyentes seleccionados independientemente de R14; R13 se selecciona de alquilo (C1-4), cicloalquilo (C3-6), bencilo alquilcarbonilo (C1-4), alquilsulfonilo (C1-4), hidroxialquilo (C1- 4) y alcoxi (C1-4)-alquilo (C1-4); R14 se selecciona de alquilo (C1-4), cicloalquilo (C3-6), alcoxi (C1-4), hidroxi, fluoro y cloro; R15 se selecciona independientemente de alquilo (C1-4), hidroxialquilo (C1-4) e hidroxi; n es 0 o 1; p es (independientemente en cada aparicion) 0, 1 o 2; o una sal del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86249306P | 2006-10-23 | 2006-10-23 | |
US89199307P | 2007-02-28 | 2007-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR063499A1 true AR063499A1 (es) | 2009-01-28 |
Family
ID=39324963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070104658A AR063499A1 (es) | 2006-10-23 | 2007-10-22 | Compuestos derivados de la pirrolidona y un proceso para su preparacion |
Country Status (18)
Country | Link |
---|---|
US (1) | US7902200B2 (es) |
EP (1) | EP2086964A2 (es) |
JP (1) | JP2010507640A (es) |
KR (1) | KR20090068289A (es) |
AR (1) | AR063499A1 (es) |
AU (1) | AU2007310608A1 (es) |
BR (1) | BRPI0718504A2 (es) |
CA (1) | CA2667435A1 (es) |
CL (1) | CL2007003033A1 (es) |
CO (1) | CO6160318A2 (es) |
IL (1) | IL198142A0 (es) |
MX (1) | MX2009004362A (es) |
NO (1) | NO20091599L (es) |
PE (1) | PE20081467A1 (es) |
RU (1) | RU2009114982A (es) |
TW (1) | TW200825063A (es) |
UY (1) | UY30660A1 (es) |
WO (1) | WO2008050101A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080280872A1 (en) * | 2004-02-18 | 2008-11-13 | Craig Johnstone | Benzamide Derivatives and Their Use as Glucokinase Activating Agents |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
BRPI0622261A2 (pt) * | 2005-07-09 | 2011-08-09 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
SA07280576B1 (ar) * | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
MX2011001333A (es) | 2008-08-04 | 2011-03-15 | Astrazeneca Ab | Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad. |
GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
WO2010150280A1 (en) * | 2009-06-22 | 2010-12-29 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (gk) activators |
JP2013500961A (ja) | 2009-07-31 | 2013-01-10 | カディラ ヘルスケア リミテッド | グルコキナーゼ(gk)アクチベーターとしての置換ベンズアミド誘導体 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20160304496A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2750393A (en) * | 1954-12-01 | 1956-06-12 | Sterling Drug Inc | Iodinated 5-henzamidotetrazoles and preparation thereof |
US2967194A (en) * | 1958-05-15 | 1961-01-03 | Pennsalt Chemicals Corp | 4-trifluoromethylsalicylamides |
FR1526074A (fr) | 1967-03-22 | 1968-05-24 | Rech S Ind S O R I Soc D | Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation |
GB1352415A (en) | 1970-05-03 | 1974-05-08 | Boots Co Ltd | Esters of substituted nicotine acids |
FR2088019A1 (en) | 1970-05-08 | 1972-01-07 | Rabot Ets David | Esters of 2 and 6-substituted nicotinic acids - with vasomotor active |
CS173097B1 (es) | 1972-12-01 | 1977-02-28 | ||
GB1400540A (en) * | 1972-12-06 | 1975-07-16 | Smith Kline French Lab | Salicylamides and compositions thereof |
US4009174A (en) * | 1972-12-08 | 1977-02-22 | The Boots Company Limited | Esters of substituted nicotinic acids |
GB1437800A (en) * | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
JPS5734314B2 (es) | 1973-12-22 | 1982-07-22 | ||
GB1561350A (en) * | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
FR2344284A1 (fr) * | 1976-03-17 | 1977-10-14 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs |
GB1588242A (en) | 1977-10-28 | 1981-04-23 | May & Baker Ltd | N-(tetrazol-5-yl)-salicylamide derivatives |
US4474792A (en) * | 1979-06-18 | 1984-10-02 | Riker Laboratories, Inc. | N-Tetrazolyl benzamides and anti-allergic use thereof |
JPS5721320A (en) | 1980-07-11 | 1982-02-04 | Chugai Pharmaceut Co Ltd | Blood sugar level depressing agent |
JPS5775962A (en) | 1980-10-29 | 1982-05-12 | Shionogi & Co Ltd | 2-alkoxybenzamide derivative |
FR2493848B2 (fr) * | 1980-11-07 | 1986-05-16 | Delalande Sa | Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique |
JPS5869812A (ja) | 1981-10-22 | 1983-04-26 | Chugai Pharmaceut Co Ltd | 血糖降下剤 |
JPS59139357A (ja) * | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
JPS61205937A (ja) | 1985-03-09 | 1986-09-12 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀カラ−写真感光材料 |
JPS62142168A (ja) | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
JPS62158252A (ja) | 1985-12-28 | 1987-07-14 | Kirin Brewery Co Ltd | 4−アミノピリジンベンズアミド誘導体 |
CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
JP2852659B2 (ja) | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
DE3822449A1 (de) | 1988-07-02 | 1990-01-04 | Henkel Kgaa | Oxidationshaarfaerbemittel mit neuen kupplern |
JPH04300832A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 2,4−ジアミノ−1,3,5−トリアジン誘導体を有 効成分とするロイコトリエン拮抗剤 |
JPH04300874A (ja) | 1991-03-29 | 1992-10-23 | Tsumura & Co | 新規2,4−ジアミノ−1,3,5−トリアジン誘導体 |
US5258407A (en) * | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5466715A (en) * | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
US5273986A (en) * | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
JPH0627025A (ja) | 1992-07-06 | 1994-02-04 | Toto Ltd | 分子認識機能膜及びこれを用いたセンサー |
EP0619116A3 (en) | 1993-04-05 | 1994-11-23 | Hoechst Japan | Use of synthetic retinoids for osteopathy. |
GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
US5661153A (en) * | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
US5792109A (en) | 1994-09-01 | 1998-08-11 | Leland L. Ladd | Irrigation pump and system |
JPH08143565A (ja) | 1994-11-16 | 1996-06-04 | Fujisawa Pharmaceut Co Ltd | ベンズアミド化合物 |
US5510478A (en) * | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
US5672750A (en) * | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
US5849735A (en) * | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
JPH08301760A (ja) | 1995-05-10 | 1996-11-19 | Shiseido Co Ltd | 皮膚外用剤 |
JP3168915B2 (ja) | 1995-05-25 | 2001-05-21 | 田辺製薬株式会社 | 医薬組成物 |
US5712270A (en) * | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
JP3735741B2 (ja) | 1995-11-24 | 2006-01-18 | 株式会社大塚製薬工場 | 縮環ピリミジン誘導体 |
JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
FR2757852B1 (fr) * | 1996-12-31 | 1999-02-19 | Cird Galderma | Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations |
JPH10212271A (ja) | 1997-01-31 | 1998-08-11 | Zeria Pharmaceut Co Ltd | N−置換ベンゾイルアミン誘導体、それを含有する医薬及び該化合物の製造中間体 |
JPH1129480A (ja) | 1997-05-12 | 1999-02-02 | Otsuka Pharmaceut Factory Inc | 縮環ピリミジン誘導体を含有する医薬組成物 |
BR9810456A (pt) * | 1997-06-27 | 2001-09-25 | Fujisawa Pharmaceutical Co | Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico |
US6242474B1 (en) * | 1997-06-27 | 2001-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Aromatic ring derivatives |
US6613942B1 (en) * | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6114483A (en) | 1997-08-27 | 2000-09-05 | E. I. Du Pont De Nemours And Company | Polymerization of olefins |
EP1048659A4 (en) | 1997-11-12 | 2002-11-20 | Inst Med Molecular Design Inc | RETINOID RECEPTOR AGONISTS |
GB9725298D0 (en) | 1997-11-28 | 1998-01-28 | Zeneca Ltd | Insecticidal thiazole derivatives |
JP4253126B2 (ja) * | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ppar−ガンマ調節剤 |
DE19816780A1 (de) * | 1998-04-16 | 1999-10-21 | Bayer Ag | Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide |
GB9811969D0 (en) * | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
US6197798B1 (en) * | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
US6610846B1 (en) * | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
RU2242469C2 (ru) * | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
AU1917201A (en) * | 1999-11-18 | 2001-05-30 | Centaur Pharmaceuticals, Inc. | Amide therapeutics and methods for treating inflammatory bowel disease |
EP1259485B1 (en) * | 2000-02-29 | 2005-11-30 | Millennium Pharmaceuticals, Inc. | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
EP1132381A1 (en) | 2000-03-08 | 2001-09-12 | Cermol S.A. | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them |
US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
ATE286036T1 (de) * | 2000-05-03 | 2005-01-15 | Hoffmann La Roche | Heteroaromatische alkynylphenyl-verbindungen als glukokinase-aktivatoren |
EP1336605B1 (en) * | 2000-11-22 | 2006-04-12 | Astellas Pharma Inc. | Substituted phenol derivatives or salts thereof as inhibitors of coagulation factor x |
WO2002046173A1 (en) * | 2000-12-06 | 2002-06-13 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
CN1289072C (zh) * | 2000-12-22 | 2006-12-13 | 石原产业株式会社 | 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂 |
US20040077697A1 (en) | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
SE0102299D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
PL368129A1 (en) * | 2001-08-09 | 2005-03-21 | Ono Pharmaceutical Co, Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
EP1336607A1 (en) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
CA2488161A1 (en) | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
EP1600442B1 (en) * | 2003-02-26 | 2018-01-17 | Msd K.K. | Heteroarylcarbamoylbenzene derivative |
GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
US20050197371A1 (en) * | 2003-11-13 | 2005-09-08 | Ambit Biosciences Corporation | Urea derivatives as PDGFR modulators |
JP4707560B2 (ja) | 2003-12-29 | 2011-06-22 | Msd株式会社 | 新規2−ヘテロアリール置換ベンズイミダゾール誘導体 |
TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
ATE524467T1 (de) | 2005-04-25 | 2011-09-15 | Merck Patent Gmbh | Neuartige aza-heterozyklen als kinase-inhibitoren |
EP1891069A1 (en) * | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
BRPI0622261A2 (pt) * | 2005-07-09 | 2011-08-09 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
WO2007017649A1 (en) * | 2005-08-09 | 2007-02-15 | Astrazeneca Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
EP1951707A1 (en) * | 2005-11-01 | 2008-08-06 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
-
2007
- 2007-10-19 TW TW096139393A patent/TW200825063A/zh unknown
- 2007-10-22 BR BRPI0718504-9A patent/BRPI0718504A2/pt not_active Application Discontinuation
- 2007-10-22 CL CL200703033A patent/CL2007003033A1/es unknown
- 2007-10-22 EP EP07824267A patent/EP2086964A2/en not_active Withdrawn
- 2007-10-22 AR ARP070104658A patent/AR063499A1/es unknown
- 2007-10-22 RU RU2009114982/04A patent/RU2009114982A/ru not_active Application Discontinuation
- 2007-10-22 AU AU2007310608A patent/AU2007310608A1/en not_active Abandoned
- 2007-10-22 KR KR1020097010059A patent/KR20090068289A/ko not_active Application Discontinuation
- 2007-10-22 MX MX2009004362A patent/MX2009004362A/es not_active Application Discontinuation
- 2007-10-22 WO PCT/GB2007/004018 patent/WO2008050101A2/en active Application Filing
- 2007-10-22 JP JP2009533935A patent/JP2010507640A/ja not_active Withdrawn
- 2007-10-22 PE PE2007001425A patent/PE20081467A1/es not_active Application Discontinuation
- 2007-10-22 US US11/876,370 patent/US7902200B2/en not_active Expired - Fee Related
- 2007-10-22 CA CA002667435A patent/CA2667435A1/en not_active Abandoned
- 2007-10-29 UY UY30660A patent/UY30660A1/es unknown
-
2009
- 2009-04-16 IL IL198142A patent/IL198142A0/en unknown
- 2009-04-20 CO CO09039732A patent/CO6160318A2/es unknown
- 2009-04-22 NO NO20091599A patent/NO20091599L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CO6160318A2 (es) | 2010-05-20 |
RU2009114982A (ru) | 2010-11-27 |
PE20081467A1 (es) | 2008-12-07 |
WO2008050101A2 (en) | 2008-05-02 |
CL2007003033A1 (es) | 2008-05-16 |
TW200825063A (en) | 2008-06-16 |
MX2009004362A (es) | 2009-05-05 |
IL198142A0 (en) | 2009-12-24 |
EP2086964A2 (en) | 2009-08-12 |
KR20090068289A (ko) | 2009-06-25 |
NO20091599L (no) | 2009-07-21 |
CA2667435A1 (en) | 2008-05-02 |
JP2010507640A (ja) | 2010-03-11 |
US7902200B2 (en) | 2011-03-08 |
US20080171734A1 (en) | 2008-07-17 |
UY30660A1 (es) | 2008-05-31 |
AU2007310608A1 (en) | 2008-05-02 |
WO2008050101A3 (en) | 2008-07-17 |
BRPI0718504A2 (pt) | 2013-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR063499A1 (es) | Compuestos derivados de la pirrolidona y un proceso para su preparacion | |
RU2436780C2 (ru) | Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы | |
AR063393A1 (es) | Derivados de benzoil amino heterociclilos utiles en el tratamiento de enfermedades originadas por la glk | |
AR048495A1 (es) | Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk | |
UY28578A1 (es) | Derivados de amida | |
HRP20151435T1 (hr) | Diamino heterociklički karboksamidni spoj | |
TW200602028A (en) | Compounds | |
AR055074A1 (es) | Derivados de heteroaril benzamidas como activadores de glk en el tratamiento de diabetes. procesos de obtencion y composiciones farmaceuticas. | |
TW200640879A (en) | Amide derivatives | |
BRPI0612888B8 (pt) | anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica | |
RS51137B (sr) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
MY140868A (en) | Amide derivatives | |
RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
RU2009117705A (ru) | Производные 2-аминокарбонилпиридина | |
PE20080890A1 (es) | DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES | |
ATE402174T1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
NO20081970L (no) | Sulfonamidderivat med PGD2-reseptorantagonistaktivitet | |
NO20061151L (no) | Succinat- og malonatsalt av trans-4-((ir,3s)-6-klor-3-fenylindan-i-yl)-1,2,2-trimetylpiperazin og anvendelsen som et medikament | |
RU2008145225A (ru) | Соединения индазола и способы ингибирования cd7 | |
AR055563A1 (es) | Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
PE20090550A1 (es) | Composicion farmaceutica solida que comprende un derivado de bencimidazol y un agente de control de ph | |
DE602005021150D1 (de) | 3-substituierte pyridinderivate als h3-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |